PLI has been the subject of a number of other research reports. TD Securities restated a speculative buy rating and set a C$4.50 price objective on shares of ProMetic Life Sciences in a report on Wednesday, September 28th. Scotiabank reiterated an outperform rating and issued a C$5.00 target price on shares of ProMetic Life Sciences in a report on Thursday, October 13th. Royal Bank Of Canada reiterated an outperform rating on shares of ProMetic Life Sciences in a report on Thursday, August 25th. Finally, CIBC lowered their target price on ProMetic Life Sciences from C$5.00 to C$4.85 in a report on Thursday, August 25th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of C$4.84.
Shares of ProMetic Life Sciences (TSE:PLI) opened at 3.11 on Thursday. ProMetic Life Sciences has a 52-week low of $1.67 and a 52-week high of $3.62. The company’s 50 day moving average price is $2.95 and its 200 day moving average price is $3.00. The stock’s market capitalization is $1.88 billion.
ProMetic Life Sciences Company Profile
ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.